Our platform provides high quality screening sets designed to maximise chemical space coverage while maintaining chemical tractability for hit optimisation. Physiochemical, size and PAINS filters eliminate undesirable attributes prior to compound selection. Importantly, we validate all compounds in our screening sets for identity, purity and aqueous solubility by NMR spectroscopy and LCMS, thereby greatly reducing the incidence of false positives. In addition to our standard screening sets we have more than 6000 additional fragments and near neighbours available for testing. This enables libraries to be tailored for specific classes of targets if desired. The extended collection includes analogues of primary screening compounds to enable rapid hit follow-up.
Screening cascades are tailored for each target. We work with you to determine which primary and secondary screens best suit your target, considering such factors as protein size, stability and production yields and the availability of natural substrates or inhibitors. SPR assay development can be provided as an independent service or to establish conditions prior to fragment screening. MFP can assist with protein production, including isotope labeling for protein-detect NMR. Selective labeling strategies can be designed for protein-detect NMR of large proteins.
Multiple screening formats are available including ligand-detect NMR and SPR. Fluorine NMR is available as an additional detection method. HSQC NMR can be used to validate hits and identify binding sites. Crystallography services are available to initiate a structure-based drug design program using the Australian Synchrotron at Monash.
We offer structure-activity relationships (SAR) by catalog compound sourcing. And our library is designed such that all compounds in our screening sets have at least 10 analogues available for immediate purchase. This enables us to establish SAR in a rapid and cost-effective manner prior to commencing a chemistry program.
MFP is located within the Monash Institute of Pharmaceutical Sciences, which provides ready access to medicinal chemistry expertise to elaborate fragment hits into higher affinity lead compounds. MFP uses our highly efficient REFiL strategy, enabling the rapid exploration of chemical space without the need for a large chemistry program. By combining the efficiency of parallel chemical synthesis with off-rate screening by SPR we can rapidly synthesize libraries of fragment analogues in plate-format to explore SAR along an expansion vector to identify new binding interactions.